New Drug Trial Targets KRAS-Mutated Colorectal Cancer
A new clinical trial evaluates a drug combination for patients with a specific genetic mutation in metastatic colorectal cancer.
Updated on Oct. 24, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies prioritize patient outcomes when researching new combination cancer therapies?
Genmab and Incyte have launched a new Phase 1/2 clinical trial to test a combination of petosemtamab and INCB161734 alongside standard chemotherapy. This study targets a new first-line treatment approach for patients with metastatic colorectal cancer harboring specific KRAS G12D mutations.
Why it matters
Colorectal cancer cases with KRAS mutations remain difficult to treat, and this collaboration seeks to address a significant unmet medical need for patients with the G12D mutation. Combining these novel agents with existing therapies aims to improve outcomes for this specific cancer subtype.
This Phase 1/2 clinical trial investigates a combination of petosemtamab and INCB161734 with standard-of-care chemotherapy in patients with KRAS G12D-mutated metastatic colorectal cancer. The overall efficacy and safety of this investigational regimen remain to be determined by the study.
The players
Genmab
A biotechnology company focused on developing antibody-based therapies for cancer.
Incyte
A biopharmaceutical company specializing in the discovery and development of oncology treatments.
The details
The trial evaluates the combination of KRAS G12D inhibition with LGR5-targeted EGFR inhibition and chemotherapy. By using these agents with complementary mechanisms, researchers hope to block tumor growth more effectively than current options. Genmab is leading the study, while Incyte is providing the clinical supply of INCB161734 and co-funding the trial.
Timeline
October 24, 2026: Genmab and Incyte announced the launch of their clinical trial collaboration.
Health Landscape
This investigation reflects the broader movement toward precision oncology that uses specific genetic mutations to guide treatment. It sits among numerous ongoing studies tracked by the clinical trial information portal that aim to move beyond traditional, non-specific chemotherapy.
If you or a loved one are managing metastatic colorectal cancer, it is worth discussing with your oncologist whether genetic testing for KRAS G12D mutations has been performed. This information is key to understanding which clinical trials or targeted therapies might be appropriate to explore.
The takeaway
Targeted therapies are increasingly important for managing metastatic colorectal cancer driven by specific genetic mutations. Patients should talk to their oncology team about the role of genetic screening in evaluating new treatment opportunities.
Further reading
For more information on the current state of cancer research, explore our Cancer section.
More information
To search for active studies and trial details, visit the clinical trial information portal.
Live Poll
Do you trust that pharmaceutical companies prioritize patient outcomes when researching new combination cancer therapies?
